Announcements and Circulars-宜明昂科英文

Investor Relations

Information Disclosure

Announcements and Circulars Financial Reports Listing Documents

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NSCLC

SUPPLEMENTAL ANNOUNCEMENT - DISCLOSEABLE TRANSACTION IN RELATION TO THE DISPOSAL OF A SUBSIDIARY

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2024

DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF NMOSD

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2024

VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE NMPA FOR A PHASE II CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF LUPUS NEPHRITIS

Next Day Disclosure Return

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

PLACING OF NEW H SHARES UNDER GENERAL MANDATE

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM0306

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIALS OF IMM27M

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) IN COMBINATION WITH AZACITIDINE FOR THE FIRST-LINE TREATMENT OF CMML

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024

INSIDE INFORMATION - PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PROGRAMME BY THE COMPANY

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE IB CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF SLE

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2024

总计 89 12 3 4 5